Meta-analysis: polymorphisms in TNF-α gene promoter and Crohn’s disease: Meta-analysis: TNF-α and Crohn’s disease

Z. Han,C. Li,S. Han,Y. Han,J. Qiu,Y. Shi,J. Wang,A. Sun,J. Ding,K. Wu,D. Fan
DOI: https://doi.org/10.1111/j.1365-2036.2010.04340.x
IF: 9.524
2010-01-01
Alimentary Pharmacology & Therapeutics
Abstract:Background Tumour necrosis factor alpha (TNF-alpha) is involved in the pathogenesis of Crohn's disease (CD). However, results on the association between the polymorphisms in TNF-alpha promoter and the risk of CD are inconsistent. Aim To perform a quantitative synthesis for the genetic polymorphisms in TNF-alpha promoter and CD risk. Methods Databases were searched (up to 2009) and 31 studies were included. Risks of CD associated with the polymorphisms in TNF-alpha promoter were assessed. Results Overall, individuals with -1031 TC+CC genotype had a slightly increased risk to develop CD compared with individuals with -1031 TT genotype (OR, 1.32; 95% CI, 1.03-1.70). In the further stratified analysis, we found Asians with the -1031T>C, -863 C>A and -857 C>T variant polymorphisms have almost one and a half CD risk compared with other genotypes (OR, 1.58; 95% CI, 1.16-2.15; OR, 1.55; 95% CI, 1.18-2.02; OR, 1.54; 95% CI, 1.19-1.99 respectively). We did not find -308 G>A variant associated with CD location and disease behaviours in stratified analysis. Conclusions TNF-alpha polymorphisms in the promoter region might be used as a biomarker for CD risk prediction. Larger studies with mixed ethnicity subjects and stratified by clinical and sub clinical characteristics are needed to validate our findings.
What problem does this paper attempt to address?